---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-071896"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2023-12-20T23:59:59+00:00"
generated_at: "2026-06-07T09:50:47.925437+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Atara closes expanded tab-cel partnership with Pierre Fabre; receives ~$27M upfront, up to $640M total

## Summary
- Pierre Fabre gets development, manufacturing, commercialization rights for tab-cel in US and all remaining markets.
- Atara receives ~$27M cash upfront and initial inventory purchase; potential milestones up to $640M total.
- Potential $100M in regulatory milestones through BLA approval; significant double-digit tiered royalties on net sales.
- Pierre Fabre to reimburse global development costs through BLA transfer; manufacturing transition planned at BLA transfer.
- Atara plans to submit tab-cel BLA for PTLD to FDA in Q2 2024.

## SEC filing metadata
- accession: 0000950170-23-071896
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2023-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000095017023071896/0000950170-23-071896-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000095017023071896/atra-20231220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-071896
- JSON: https://secwatch.observer/filing/0000950170-23-071896.json
- Plain text: https://secwatch.observer/filing/0000950170-23-071896.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.